Big pharma consolidation: the tectonic plates shift
The takeover of Celgene has disrupted pharma’s conventional wisdom on which companies should merge and when. This is how things now stand.
Why Novo Nordisk should buy Amarin
Pfizer is said to be interested in Amarin, but the Danish group’s need for a growth injection is greater.
JP Morgan 2019 day one roundup – happy days are here again
The takeovers of Loxo and Celgene put M&A back on the agenda, and positive clinical readouts from Sage and Axsome add to the celebratory mood.
JP Morgan preview – price hikes come back with a bang in 2019
Allergan, Biogen, Bristol-Myers Squibb and Lilly follow Pfizer and Merck & Co on price increases, and there could be more to come at JP Morgan.
Achillion’s first oral Soliris rival hits the buffers
Achillion’s pivot to a next-gen project in paroxysmal nocturnal haemoglobinuria is an admission that its first attempt to compete with Alexion’s Soliris has fallen short.
Upcoming events – Verona waits to exhale and a new test for Alexion
Verona Pharma needs another COPD win, while Alexion seeks a new use for its Soliris successor.
Ra joins the challenge to Alexion’s Soliris stranglehold
Promising data in myasthenia gravis, plus a pledge to compete on price, means that Ra Pharmaceuticals’ zilucoplan could soon give Alexion a headache – and others are…
Ash 2018 event analyzer – Losers edge out winners in year’s final major meeting
Autolus leads winners in spite of scepticism over its CAR-T, and gene therapies disappoint.
Biotech's big-bucks buybacks begin to burn
If big biotech cannot deliver innovation investors might start demanding shareholder payout plans that look more like big pharma's.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.